Iol Chemcials And Pharmaceuticals

IOL Chemicals and Pharmaceuticals, headquartered in India and operating in the Pharmaceutical Preparation Manufacturing industry, has publicly disclosed its carbon emissions and climate commitments.

For the most recent reporting year, 2025, the company reported total Scope 1 emissions of 45,025,000 kg CO2e, Scope 2 emissions of 6,019,880 kg CO2e, and Scope 3 emissions of 93,042,000 kg CO2e. These Scope 3 emissions include 51,088,132 kg CO2e from purchased goods and services.

Looking at previous years, in 2024, IOL Chemicals and Pharmaceuticals reported Scope 1 emissions of 49,521,000 kg CO2e, Scope 2 emissions of 6,179,000 kg CO2e, and Scope 3 emissions of 108,357,150 kg CO2e. For 2023, the company's total emissions were approximately 130,808,000 kg CO2e, comprising Scope 1 emissions of 23,786,000 kg CO2e, Scope 2 emissions of 6,134,450 kg CO2e, and Scope 3 emissions of 100,887,000 kg CO2e. In 2022, total emissions were around 26,879,000 kg CO2e, with Scope 1 emissions of 24,928,000 kg CO2e, Scope 2 emissions of 1,171,000 kg CO2e, and Scope 3 emissions of 779,000 kg CO2e.

IOL Chemicals and Pharmaceuticals has set ambitious Science Based Targets initiative (SBTi) validated targets. The company commits to achieving net-zero greenhouse gas emissions across its value chain by FY2050.

For near-term reductions, IOL Chemicals and Pharmaceuticals aims to reduce absolute Scope 1 and 2 GHG emissions by 58.8% by FY2033, using FY2022 as a base year. Additionally, the company commits to reducing absolute Scope 3 GHG emissions by 35% within the same timeframe.

For long-term reductions towards its net-zero goal, the company plans to reduce absolute Scope 1 and 2 GHG emissions by 90% by FY2050 from a FY2022 base year. Concurrently, it also commits to reducing absolute Scope 3 GHG emissions by 90% by FY2050. These targets include land-related emissions and removals from bioenergy feedstocks.